SCNI News

Scinai CEO Updates Shareholders on CDMO Growth and Extended Runway Following Completed Financing

Scinai Immunotherapeutics Announces Closing of $4.0 Million Financing Through a Private Placement and Warrant Inducement

Scinai Expands CDMO Business with $5.1 Million Development and Clinical Manufacturing Agreement

Scinai Regains Compliance with Nasdaq Minimum Bid Price Requirement

Scinai Concludes PC111 Arrangements and Refocuses Capital on NanoAb Platform and Growing CDMO Business

Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum

Scinai Strengthens CDMO Leadership with Appointment of Eran Kuratz as Head of Supply Chain and Business Process Administration

Scinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth Initiatives

Scinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facility

Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe